TxCell Receives US Patent For Ovasave To Treat IBD

TxCell Receives US Patent For Ovasave To Treat IBD
A key patent was recently granted by the United States Patent and Trademark Office (USPTO) to TxCell SA for its lead product Ovasave® to address inflammatory bowel disease (IBD). The patent will protect Ovasave until 2030. TxCell SA is a biotechnology company committed to developing cost-effective, innovative and personalized T-cell immunotherapies through the utilization of antigen specific regulatory T-cells (Ag-Tregs) that might address the unmet needs

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *